Abstract #3703

Noninvasive assessment of treatment response to histone deacetylase inhibitor and radiation for pediatric diffuse midline glioma using hyperpolarized carbon-13 metabolic imaging

Ilwoo Park¹, Adam Autry², Xiaodong Yang³, Yuying Zhai³, Renuka Sriram², Dave Korenchan², John Kurhanewicz², Adam Cunha⁴, I-Chow Hsu⁴, and Sabine Mueller⁵

¹Radiology, Chonnam National University, Gwangju, Republic of Korea, ²Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, United States, ³Neurology, University of California San Francisco, San Francisco, CA, United States, ⁴Radiation Oncology, University of California San Francisco, San Francisco, CA, United States, ⁵Neurology, Neurosurgery and Pediatrics, University of California San Francisco, San Francisco, CA, United States

Diffuse midline glioma is one of the most difficult pediatric cancers to treat. This study investigated the feasibility of ¹³C magnetic resonance metabolic imaging of hyperpolarized [1-¹³C]pyruvate for monitoring response to novel therapies in diffuse midline glioma. Treatment with panobinostat was associated with a reduction in hyperpolarized lactate and a reduced LDHA activity in an in vitro experiment. Radiotherapy led to a reduction in the ratio of lactate to pyruvate in rats bearing diffuse midline glioma. The results suggest that hyperpolarized ¹³C metabolic imaging may provide an early noninvasive biomarker to monitor therapy response in diffuse midline glioma.

This abstract and the presentation materials are available to members only; a login is required.

Join Here